Sep-04-20 Initiated H.C. Wainwright
Buy
$11
Aug-28-20 Initiated Wedbush
Outperform
$12
Sep-19-18 Initiated Robert W. Baird
Outperform
May-14-18 Initiated Goldman
Neutral
$17
May-14-18 Initiated Evercore ISI
Outperform
$26
Mar-02-21 12:30PM Feb-24-21 07:00AM Feb-23-21 07:25AM Feb-22-21 06:21AM Feb-11-21 07:00AM Jan-19-21 03:25PM Jan-13-21 08:39AM Jan-11-21 06:00AM Dec-22-20 12:20PM 04:37AM Dec-17-20 03:35PM 08:10AM 06:55AM Dec-14-20 07:07AM Dec-07-20 08:29AM Nov-25-20 07:00AM Nov-15-20 08:39AM 06:57AM Nov-13-20 07:05AM Nov-11-20 07:00AM Nov-10-20 06:20AM Nov-09-20 04:25PM 09:00AM Nov-05-20 09:43AM Oct-26-20 04:05PM Oct-20-20 01:03PM Oct-19-20 12:32PM Oct-12-20 03:41PM Sep-16-20 05:05PM Sep-15-20 07:23AM Sep-11-20 03:00PM Sep-09-20 01:15PM Sep-04-20 09:38AM Sep-02-20 08:52AM Aug-28-20 10:16AM Aug-19-20 01:56PM Aug-11-20 06:30AM Aug-05-20 11:59AM Jun-12-20 09:45AM Jun-10-20 08:12PM May-28-20 04:10PM May-20-20 11:28AM 07:15AM 07:05AM May-15-20 11:46AM 07:30AM May-14-20 07:30AM May-13-20 08:00AM May-12-20 06:20AM May-07-20 12:30PM Apr-23-20 08:00AM Mar-17-20 08:00AM Mar-12-20 10:39AM Mar-10-20 06:20AM Mar-06-20 11:30AM Feb-25-20 04:05PM Feb-19-20 11:30AM Feb-04-20 06:58AM Jan-28-20 07:12AM Jan-27-20 04:05PM Dec-23-19 10:24AM Dec-09-19 05:45PM Nov-26-19 11:07AM 08:00AM Nov-25-19 08:00AM Nov-18-19 06:30AM Nov-12-19 07:45AM 06:30AM Nov-07-19 08:00AM Oct-26-19 06:25PM Oct-07-19 07:00AM Sep-23-19 12:50PM Sep-18-19 05:55PM Sep-17-19 05:25PM Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. PR Newswire -8.48%
Sep-03-19 04:05PM 01:45PM 07:00AM Aug-28-19 10:45AM Aug-27-19 08:00AM Aug-21-19 08:45PM Aug-20-19 01:15PM Aug-15-19 11:20PM Aug-14-19 08:55PM Aug-12-19 06:20PM Aug-08-19 09:05PM Aug-07-19 10:30PM 09:30PM 10:07AM 09:05AM 06:05AM Aug-06-19 05:52PM 12:55PM 10:30AM Aug-03-19 11:05AM Aug-01-19 01:15PM Jul-30-19 09:25PM Jul-29-19 01:15PM Jul-26-19 11:40PM Jul-25-19 03:09PM Jun-07-19 12:00PM
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROSS ROBERT W. Chief Medical Officer Feb 16 Sale 11.35 1,000 11,350 88,000 Feb 18 08:00 PM Goater Jeff Chief Executive Officer Feb 08 Option Exercise 3.18 2,500 7,950 264,500 Feb 09 08:00 PM FEES JESSICA See Remarks Feb 08 Sale 12.45 1,500 18,675 99,183 Feb 09 08:00 PM Goater Jeff Chief Executive Officer Feb 08 Sale 12.50 2,500 31,250 262,000 Feb 09 08:00 PM Goater Jeff Chief Executive Officer Feb 01 Option Exercise 3.18 2,500 7,950 264,500 Feb 03 08:00 PM FEES JESSICA See Remarks Feb 01 Sale 11.19 1,500 16,785 100,683 Feb 03 08:00 PM Goater Jeff Chief Executive Officer Feb 01 Sale 10.69 2,500 26,718 262,000 Feb 03 08:00 PM Goater Jeff Chief Executive Officer Jan 19 Option Exercise 3.18 5,000 15,900 267,000 Jan 21 08:17 PM Goater Jeff Chief Executive Officer Jan 19 Sale 13.00 5,000 65,000 262,000 Jan 21 08:17 PM ROSS ROBERT W. Chief Medical Officer Jan 15 Sale 12.25 2,000 24,500 89,000 Jan 15 08:00 PM ROSS ROBERT W. Chief Medical Officer Jan 14 Sale 11.95 7,000 83,650 91,000 Jan 15 08:00 PM Atlas Venture Fund IX, L.P. 10% Owner Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM GRAYZEL DAVID S. Director Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM ROSS ROBERT W. Chief Medical Officer Dec 15 Sale 10.48 1,000 10,480 98,000 Dec 17 08:00 PM ROSS ROBERT W. Chief Medical Officer Dec 11 Sale 10.05 1,405 14,120 99,000 Dec 15 08:00 PM FEES JESSICA See Remarks Nov 25 Option Exercise 5.06 1,383 6,996 102,183 Nov 27 08:00 PM ROSS ROBERT W. Chief Medical Officer Nov 11 Sale 10.05 595 5,980 100,405 Nov 13 08:00 PM FEES JESSICA See Remarks Oct 28 Option Exercise 4.14 4,895 20,262 100,800 Oct 30 08:30 PM ROSS ROBERT W. Chief Medical Officer Oct 14 Sale 10.05 4,000 40,200 101,000 Oct 16 08:02 PM EcoR1 Capital, LLC 10% Owner Sep 01 Sale 7.14 332,780 2,376,681 4,701,081 Sep 03 04:17 PM New Enterprise Associates 14, 10% Owner May 20 Sale 3.66 420,000 1,535,562 2,892,877 May 22 04:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
